Home > Name List By t > Temsirolimus Canada

CAS No 162635-04-3 , Temsirolimus Search by region : Canada

  • Name: Temsirolimus
  • Synonyms: 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin;CCL-779; Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;Temsirolimus;
  • CAS Registry Number:
  • Flash Point: 587.8°C
  • Boiling Point: 1048.4°Cat760mmHg
  • Density: 1.2g/cm3
  • Refractive index: 1.553
  • Flash Point: 587.8°C
  • Molecular Weight: 1030.29
  • InChI: InChI=1/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+
  • Molecular Formula: C56H87NO16
  • Molecular Structure:CAS No:162635-04-3 Temsirolimus

Related products

Select to

162635-04-3 TEMSIROLIMUS

  • Canada Molcan Corporation [Manufacturer]
  • Tel: 905-731-5537/ 888-237-7579
  • Fax: 905-248-3843;905-731-6592
  • Address: 70 East Beaver Creek Road 39,
    Richmond Hill, Ontario, Canada L4B 3B2 null,nullCanada
Contact Supplier

Select to

1/1
References of Temsirolimus
Title: Temsirolimus
CAS Registry Number: 162635-04-3
CAS Name: Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]
Synonyms: rapamycin 42-ester with 2,2-bis-(hydroxymethyl)propionic acid
Manufacturers' Codes: CCI-779
Molecular Formula: C56H87NO16
Molecular Weight: 1030.29
Percent Composition: C 65.28%, H 8.51%, N 1.36%, O 24.85%
Literature References: Ester analog of rapamycin, q.v.; selectively inhibits mammalian target of rapamycin (mTOR). Prepn: J. S. Skotnicki et al., US 5362718 (1994 to Am. Home Prod.). Lipase-catalyzed synthesis from rapamycin: J. Gu et al., Org. Lett. 7, 3945 (2005). Clinical pharmacology: E. Raymond et al., J. Clin. Oncol. 22, 2336 (2004). Clinical study in advanced refractory renal cell carcinoma: M. B. Atkins et al., ibid. 909. Clinical evaluation in glioblastoma multiforme: E. Galanis et al., J. Clin. Oncol. 23, 5294 (2005); in breast cancer: S. Chan et al., ibid. 5314; in mantle cell lymphoma: T. E. Witzig et al., ibid. 5347.
Properties: White solid. Sol in water. Lipophilic.
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Antibiotics and Analogs.